Patent 7410781 was granted and assigned to Regeneron Pharmaceuticals, Inc. on August, 2008 by the United States Patent and Trademark Office.
Polypeptides and multimeric polypeptides capable of binding interleukin-4 (IL-4) and interluekin-13 (IL-13) which are useful therapeutically in methods of treating IL-4 and IL-13-related conditions or diseases.